Plantina has been acquired by Nutramin
E. de Groot and G. Schuitemaker, private shareholders of Plantina, have sold the company to Nutramin.
Plantina is a developer and supplier of branded food supplements primarily for the Dutch market and, to a lesser extent, for the Belgian and German markets. The company's products are marketed under the strong and renowned Plantina brand and Performax in Germany. The Plantina brand is known for its superior quality and effectiveness due to its choice of raw materials and suppliers, and its relative high dosing.
Founded in 1982, Nutramin is a developer and supplier of food supplements with a focus on healthcare professionals, doctors and therapists. Additionally, the company provides informative services such as conferences in congresses, master classes and training sessions which highlight its academic and professional background.
Oaklins' team in the Netherlands advised the seller in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more